Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Department of Mathematics, Imperial College London, London, London, UK.
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):813-816. doi: 10.1136/jnnp-2017-317234. Epub 2018 Jan 13.
Several studies suggest that multiple rare genetic variants in genes causing monogenic forms of neurodegenerative disorders interact synergistically to increase disease risk or reduce the age of onset, but these studies have not been validated in large sporadic case series.
We analysed 980 neuropathologically characterised human brains with Alzheimer's disease (AD), Parkinson's disease-dementia with Lewy bodies (PD-DLB), frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) and age-matched controls. Genetic variants were assessed using the American College of Medical Genetics criteria for pathogenicity. Individuals with two or more variants within a relevant disease gene panel were defined as 'oligogenic'.
The majority of oligogenic variant combinations consisted of a highly penetrant allele or known risk factor in combination with another rare but likely benign allele. The presence of oligogenic variants did not influence the age of onset or disease severity. After controlling for the single known major risk allele, the frequency of oligogenic variants was no different between cases and controls.
A priori, individuals with AD, PD-DLB and FTD-ALS are more likely to harbour a known genetic risk factor, and it is the burden of these variants in combination with rare benign alleles that is likely to be responsible for some oligogenic associations. Controlling for this bias is essential in studies investigating a potential role for oligogenic variation in neurodegenerative diseases.
多项研究表明,导致单基因神经退行性疾病的基因中的多个罕见遗传变异会协同作用,增加疾病风险或降低发病年龄,但这些研究尚未在大型散发性病例系列中得到验证。
我们分析了 980 例经神经病理学特征分析的阿尔茨海默病 (AD)、帕金森病伴路易体痴呆 (PD-DLB)、额颞叶痴呆伴肌萎缩侧索硬化症 (FTD-ALS) 患者和年龄匹配的对照组的脑组织。使用美国医学遗传学学院致病性标准评估遗传变异。在相关疾病基因面板中具有两个或更多变异的个体被定义为“寡基因”。
大多数寡基因变异组合由高外显率等位基因或已知风险因素与另一个罕见但可能良性的等位基因组合而成。寡基因变异的存在并不影响发病年龄或疾病严重程度。在控制单个已知主要风险等位基因后,寡基因变异在病例和对照组之间的频率没有差异。
根据先验知识,AD、PD-DLB 和 FTD-ALS 患者更有可能携带已知的遗传风险因素,这些变异与罕见良性等位基因的共同负担可能是某些寡基因关联的原因。在研究寡基因变异在神经退行性疾病中潜在作用的研究中,控制这种偏差至关重要。